|
Bloomage BioTechnology Corporation Limited (688363.SS) DCF Valuation
CN | Basic Materials | Chemicals - Specialty | SHH
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Bloomage BioTechnology Corporation Limited (688363.SS) Bundle
Explore the financial potential of Bloomage BioTechnology Corporation Limited (688363SS) with our user-friendly DCF Calculator! Enter your projections for growth, profit margins, and expenses to determine the intrinsic value of Bloomage BioTechnology Corporation Limited (688363SS) and enhance your investment strategy.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,885.6 | 2,632.7 | 4,947.8 | 6,359.2 | 6,075.9 | 8,379.2 | 11,555.5 | 15,935.9 | 21,976.8 | 30,307.6 |
| Revenue Growth, % | 0 | 39.63 | 87.93 | 28.53 | -4.45 | 37.91 | 37.91 | 37.91 | 37.91 | 37.91 |
| EBITDA | 766.3 | 840.4 | 1,063.7 | 1,382.2 | 1,007.3 | 2,218.4 | 3,059.3 | 4,219.1 | 5,818.4 | 8,024.0 |
| EBITDA, % | 40.64 | 31.92 | 21.5 | 21.74 | 16.58 | 26.48 | 26.48 | 26.48 | 26.48 | 26.48 |
| Depreciation | 62.9 | 75.0 | 161.3 | 228.6 | 292.4 | 299.2 | 412.6 | 569.1 | 784.8 | 1,082.3 |
| Depreciation, % | 3.34 | 2.85 | 3.26 | 3.6 | 4.81 | 3.57 | 3.57 | 3.57 | 3.57 | 3.57 |
| EBIT | 703.4 | 765.4 | 902.4 | 1,153.5 | 714.9 | 1,919.2 | 2,646.7 | 3,650.0 | 5,033.6 | 6,941.8 |
| EBIT, % | 37.3 | 29.07 | 18.24 | 18.14 | 11.77 | 22.9 | 22.9 | 22.9 | 22.9 | 22.9 |
| Total Cash | 2,201.5 | 2,113.0 | 2,653.5 | 2,136.9 | 1,308.8 | 4,843.7 | 6,679.8 | 9,212.0 | 12,704.0 | 17,519.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 389.0 | 402.2 | 544.9 | 450.2 | 651.6 | 898.6 | 1,239.2 | 1,709.0 | 2,356.9 |
| Account Receivables, % | 0 | 14.78 | 8.13 | 8.57 | 7.41 | 7.78 | 7.78 | 7.78 | 7.78 | 7.78 |
| Inventories | 314.5 | 476.8 | 709.1 | 1,161.5 | 1,134.5 | 1,442.2 | 1,988.9 | 2,742.8 | 3,782.6 | 5,216.5 |
| Inventories, % | 16.68 | 18.11 | 14.33 | 18.27 | 18.67 | 17.21 | 17.21 | 17.21 | 17.21 | 17.21 |
| Accounts Payable | 95.0 | 196.9 | 643.9 | 816.8 | 693.6 | 834.4 | 1,150.8 | 1,587.0 | 2,188.6 | 3,018.2 |
| Accounts Payable, % | 5.04 | 7.48 | 13.01 | 12.85 | 11.42 | 9.96 | 9.96 | 9.96 | 9.96 | 9.96 |
| Capital Expenditure | -450.2 | -762.8 | -784.2 | -696.4 | -1,030.3 | -1,619.0 | -2,232.7 | -3,079.1 | -4,246.3 | -5,856.0 |
| Capital Expenditure, % | -23.88 | -28.97 | -15.85 | -10.95 | -16.96 | -19.32 | -19.32 | -19.32 | -19.32 | -19.32 |
| Tax Rate, % | 15.56 | 15.56 | 15.56 | 15.56 | 15.56 | 15.56 | 15.56 | 15.56 | 15.56 | 15.56 |
| EBITAT | 587.5 | 651.4 | 793.1 | 985.8 | 603.7 | 1,636.7 | 2,257.2 | 3,112.8 | 4,292.8 | 5,920.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -19.3 | -485.7 | 371.5 | 96.0 | -135.7 | -51.3 | -40.3 | -55.6 | -76.6 | -105.7 |
| WACC, % | 8.53 | 8.53 | 8.54 | 8.54 | 8.53 | 8.53 | 8.53 | 8.53 | 8.53 | 8.53 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -250.3 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | -109 | |||||||||
| Terminal Value | -2,172 | |||||||||
| Present Terminal Value | -1,442 | |||||||||
| Enterprise Value | -1,692 | |||||||||
| Net Debt | -953 | |||||||||
| Equity Value | -739 | |||||||||
| Diluted Shares Outstanding, MM | 482 | |||||||||
| Equity Value Per Share | -1.53 |
What You Will Receive
- Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-populated financial data for Bloomage BioTechnology Corporation Limited (688363SS).
- Accurate Data: Access to historical financials and projected estimates (highlighted in the yellow cells).
- Flexible Forecasting: Modify essential forecast parameters such as revenue growth, EBITDA percentage, and WACC.
- Real-Time Calculations: Instantly observe how your inputs affect Bloomage's valuation.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Interface: Organized for simplicity and ease of navigation, complete with step-by-step guidance.
Key Features
- 🔍 Real-Life 688363SS Financials: Pre-filled historical and projected data for Bloomage BioTechnology Corporation Limited.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas calculate Bloomage’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Bloomage’s valuation immediately after making changes.
- Scenario Analysis: Evaluate and compare outcomes for different financial assumptions side-by-side.
How It Functions
- Download: Obtain the pre-configured Excel file containing Bloomage BioTechnology Corporation Limited’s financial data.
- Customize: Modify projections, including revenue growth, EBITDA percentage, and WACC.
- Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate multiple forecasts and compare the results instantly.
- Make Decisions: Utilize the valuation findings to inform your investment strategy.
Why Opt for This Calculator?
- Accurate Data: Utilize real financials from Bloomage BioTechnology Corporation Limited (688363SS) for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Ready-to-use calculations mean you won’t have to start from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotechnology sector.
- User-Friendly: Featuring an intuitive design and step-by-step guidance for users of all levels.
Who Should Use This Product?
- Students in Biotechnology: Explore cutting-edge biotechnological methods and apply them with real-time data.
- Researchers: Integrate advanced models into your academic projects or scientific studies.
- Investors: Evaluate your hypotheses and assess valuation results for Bloomage BioTechnology Corporation Limited (688363SS).
- Market Analysts: Enhance your analysis with a ready-to-use, customizable DCF model tailored for biotech firms.
- Entrepreneurs: Understand the valuation approaches used for significant public biotech companies like Bloomage BioTechnology Corporation Limited (688363SS).
What the Template Contains
- Historical Data: Features Bloomage BioTechnology's past financial records and foundational forecasts.
- DCF and Levered DCF Models: Comprehensive templates designed to assess Bloomage BioTechnology's intrinsic value.
- WACC Sheet: Ready-to-use calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Adjust key parameters such as growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: An extensive analysis of Bloomage BioTechnology's financial performance.
- Interactive Dashboard: Visualize valuation outcomes and projections in a dynamic format.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.